Pharma & Biotech

Biotechnology firm Arcus Biosciences is executing a strategic overhaul of its clinical development portfolio after a significant late-2025 setback in...

Investors are marking their calendars for a pivotal date in late February 2026. National Healthcare is poised to release its...

Biopharmaceutical firm aTyr Pharma (ATYR) has scheduled a critical regulatory discussion with the U.S. Food and Drug Administration (FDA) for...

Biotechnology firm Bionxt Solutions has moved a step closer to testing a novel multiple sclerosis treatment in humans. The company's...

ImmunityBio has initiated a new clinical study, marking a strategic expansion of its development pipeline. The U.S. biotechnology firm announced...

Acadia Pharmaceuticals has encountered a significant obstacle for its European expansion strategy. Market uncertainty followed the announcement of a negative...

Six months after finalizing its acquisition, Merck KGaA is hitting significant milestones in its integration of SpringWorks Therapeutics. The operational...

Replimune Group Inc. is approaching a pivotal sequence of events that will shape its future. The biopharmaceutical company’s shares last...

ImmunityBio has entered February with significant operational momentum, driven by surging revenue, greater clarity from U.S. regulators, and initial international...

A key regulatory obstacle has been cleared for Sanofi's planned $2.2 billion purchase of Dynavax Technologies, moving the major pharmaceutical...